Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul, Republic of Korea.
Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea.
Front Immunol. 2023 Mar 3;14:1098461. doi: 10.3389/fimmu.2023.1098461. eCollection 2023.
The SARS-CoV-2 coronavirus, which causes a respiratory disease called COVID-19, has been declared a pandemic by the World Health Organization (WHO) and is still ongoing. Vaccination is the most important strategy to end the pandemic. Several vaccines have been approved, as evidenced by the ongoing global pandemic, but the pandemic is far from over and no fully effective vaccine is yet available. One of the most critical steps in vaccine development is the selection of appropriate antigens and their proper introduction into the immune system. Therefore, in this study, we developed and evaluated two proposed vaccines composed of single and multiple SARS-CoV-2 polypeptides derived from the spike protein, namely, vaccine A and vaccine B, respectively. The polypeptides were validated by the sera of COVID-19-vaccinated individuals and/or naturally infected COVID-19 patients to shortlist the starting pool of antigens followed by vaccination to hACE2 transgenic mice. The spike multiple polypeptide vaccine (vaccine B) was more potent to reduce the pathogenesis of organs, resulting in higher protection against the SARS-CoV-2 infection.
引发 COVID-19 呼吸道疾病的 SARS-CoV-2 冠状病毒已被世界卫生组织（WHO）宣布为大流行，目前仍在持续。疫苗接种是结束大流行的最重要策略。尽管目前正在进行全球大流行，但已经有几种疫苗获得批准，但大流行还远未结束，也没有完全有效的疫苗。疫苗开发中最重要的步骤之一是选择适当的抗原并将其正确引入免疫系统。因此，在这项研究中，我们开发并评估了两种由来自刺突蛋白的单个和多个 SARS-CoV-2 多肽组成的提议疫苗，分别称为疫苗 A 和疫苗 B。通过 COVID-19 疫苗接种个体和/或自然感染 COVID-19 患者的血清对多肽进行验证，以确定候选抗原的起始池，然后对 hACE2 转基因小鼠进行疫苗接种。刺突多个多肽疫苗（疫苗 B）更能减轻器官的发病机制，从而对 SARS-CoV-2 感染提供更高的保护。
